(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 June 2022 (30.06.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/140448 A1

(51) International Patent Classification:
A61K 9/48 (2006.01) *A61K 31/198* (2006.01)
A61K 31/192 (2006.01) *A61P 25/16* (2006.01)

(21) International Application Number:
PCT/US2021/064693

(22) International Filing Date:
21 December 2021 (21.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/129,063	22 December 2020 (22.12.2020)	US
63/150,121	17 February 2021 (17.02.2021)	US
63/236,403	24 August 2021 (24.08.2021)	US
63/247,639	23 September 2021 (23.09.2021)	US

(71) Applicant: **AMNEAL PHARMACEUTICALS LLC** [US/US]; 400 Crossing Boulevard, Attn : Legal Dept., Bridgewater, NJ 08807 (US).

(72) Inventors: **D'SOUZA, Richard**; Amneal Pharmaceuticals LLC, Attn : Legal Dept., 400 Crossing Boulevard, Bridgewater, NJ 08807 (US). **VISSER, Hester**; Amneal Pharmaceuticals LLC, Attn : Legal Dept., 400 Crossing Boulevard, Bridgewater, NJ 08807 (US). **GUPTA, Suneel**; Amneal Pharmaceuticals LLC, Attn : Legal Dept., 400 Crossing Boulevard, Bridgewater, NJ 08807 (US).

(74) Agent: **ENDRES, Martin, P**; Florek & Endres PLLC, 552 Seventh Avenue, Suite 601, New York, NY 10018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: LEVODOPA DOSING REGIMEN




FIG. 17

(57) Abstract: The invention provides oral dosing regimens of controlled release levodopa compositions for use in treating patients with Parkinson's disease.

[Continued on next page]

WO 2022/140448 A1

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*